Capricor Therapeutics, Inc. (NASDAQ: CAPR) is making waves in the biotechnology sector with its cutting-edge approach to treating diseases with unmet medical needs. With a focus on developing transformative cell and exosome-based therapeutics, Capricor is carving out a niche in the treatment of Duchenne muscular dystrophy (DMD) and other challenging conditions. As it stands, the company is attracting significant attention from investors due to its promising pipeline and substantial potential upside.

Currently, Capricor’s market capitalization is at $1.59 billion, a testament to the growing investor confidence in its innovative healthcare solutions. The company’s flagship product, Deramiocel, is in phase 3 clinical trials,…